RxDoctor Payments Data

Loring Jacobs, MD

Internal Medicine · Henderson, NVNPI 1467525055

Payments from drug & device makers

$6,507in general payments, 2019–2025

Across 306 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$940
  • Medtronic$581
  • Amgen$433
  • Lilly USA, LLC$314
  • Pfizer$281
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,41399%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,507 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$170,512
Medicare patients
642
Services billed
1,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab15$101,493
JardianceEmpagliflozin45$55,458
XareltoRivaroxaban34$41,871
OzempicSemaglutide38$35,233
EliquisApixaban27$25,921
RybelsusSemaglutide17$19,673
FarxigaDapagliflozin Propanediol17$17,431
JanuviaSitagliptin Phosphate16$13,892
Montelukast Sodium635$6,209
Ezetimibe221$5,970
Atorvastatin Calcium745$5,918
SymbicortBudesonide/Formoterol Fumarate17$5,656
Losartan Potassium540$5,437
SynthroidLevothyroxine Sodium68$5,069
Levothyroxine Sodium493$4,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Synthroid$266$106,56183 claims
Boehringer IngelheimJardiance$135$55,45845 claims
Novo NordiskOzempic, Rybelsus$1,342$54,90655 claims
Johnson & JohnsonXarelto$13$41,87134 claims
PfizerEliquis, Paxlovid$281$30,20866 claims
AstraZenecaFarxiga, Symbicort$940$23,08734 claims
MerckJanuvia$58$13,89216 claims
Almatica Pharma LLCSertraline Hcl$20$1,742107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →